Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on Active Substances and Nitrosamine Impurities

On 26 July 2022, the EMA published a concept paper to start the process for the revision of the Guideline on the chemistry of active substances. The document dates from 2016 and does not consider the nitrosamine issue that has developed in recent years.

The critical need to revise and update this important guideline was identified when the "Lessons learnt report" on impurities in sartan medicines was compiled.

What can be expected in terms of content?
Recommendations for the prevention, risk reduction and control of N-nitrosamines, but also for other "contaminants of concern" (CoC) and potent toxins will be included. Also to be tackled are

  • Strategies for process development
  • The subject areas of raw materials, starting materials and intermediate products and their potential contamination risk
  • The use of recycled materials
  • Specific control options for nitrosamines

The EMA Quality Working Party (QWP) has appointed two rapporteurs as well as experts from different Member States with expertise in this field to the drafting group. The group will be supported by an observer from the European Directorate for Quality of Medicines (EDQM), who will work closely with the QWP expert group on nitrosamines.

What is the schedule?

The concept paper will be available for comments until 31 October 2022. Following this, a draft document will be prepared, which will then be released for comments for six months.


Source:

EMA: Concept Paper on the revision of the guideline on the chemistry of active substances
EMA: Guideline on the chemistry of active substances

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic has revised its guidance document “GMP compliance by foreign manufacturers”. The new Version 7.0 has been valid since 7 September 2026. In particular, it introduces new provisions for demonstrating the GMP compliance of manufacturers inspected by the US FDA. 
Read more
Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic has revised its Technical Interpretation “Market release and distribution in cooperation with a pre-wholesaler”. The document addresses market release and distribution where a Marketing Authorisation Holder works with a pre-wholesaler (logistics and distribution service provider).
Read more
News: Europe

IPEC Updates Two Guides on Pharmaceutical Excipients

The IPEC Federation has updated two key guides on pharmaceutical excipients. The IPEC Composition Guide for Pharmaceutical Excipients (Version 3, 2026) describes an approach for manufacturers to establish excipient composition profiles. The revised version now covers biotechnology- and fermentation-derived excipients, provides further details on component types and physicochemical characterisation, and includes an example composition profile template.
Read more
Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
Question of the Week | GMP-Verlag

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
News: Europe

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Previous
Next